<h4>Background</h4>In recent years, immunotherapy represented by programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunosuppressants has greatly changed the status of non-small cell lung cancer (NSCLC) treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.